25. October 2016 MM

Peppermint VenturePartners closes Series-C financing round of Miracor Medical Systems GmbH

Miracor’s Chairman of the Board: “We are proud to have PVP joining our Investors”

Berlin. Peppermint VenturePartners led the recent Series-C financing of Miracor Medical Systems GmbH with an investment from its Peppermint CBF-1 fund. The total amount raised in the Series-C is currently € 7 Million. Miracor seeks to complete Series-C with another € 8 Million.

Magnus Holm, Venture Partner at Peppermint, on the new investment: “Miracor has reached important milestones in recent months and we are impressed with the company’s performance and the latest clinical data on the PiCSO Impulse System, which show statistically significant reductions in infarct size and improvements in cardiac function after acute myocardial infarction (heart attack, AMI). With AMI being the single biggest contributor to the growing incidence of heart failure, its effective treatment remains a huge clinical need, despite recent developments in percutaneous coronary interventions. Miracor is targeting this important clinical and economic need by improving the outcomes of patients following AMI. We are delighted to be involved with this exciting company and look forward to now supporting Miracor in its activities.”

Miracor’s PiCSOAMI Impulse System aims to improve outcome of patients with acute myocardial infarction by improving myocardial perfusion during percutaneous coronary intervention (PCI). PiCSO therapy is provided during the stenting procedure and intermittently increases pressure in the coronary venous system which leads to an improved microcirculatory flow and improved perfusion of the infarcted area, ultimately leading to a smaller residual infarct size after AMI compared to non PiCSO treated patients. Decreased residual infarct size after AMI has shown to be directly correlated to reduced mortality and hospitalizations for heart failure.

Werner Braun, PhD, Chairman of the Board of Miracor, on Peppermints investment: “This additional investment enables us to accelerate our plans to start first clinical activities in the US. We are proud to have Peppermint join our existing investor group and look forward to a fruitful cooperation.”

 

About Peppermint VenturePartners:

Peppermint VenturePartners (www.peppermint-vp.com) is a private venture capital firm based in Berlin, investing in early-stage companies in the healthcare sector. Its focus is on companies working in the fields of medical technology, diagnostics and digital health, as well as platform technologies in biomedicine that stand out as a result of their innovative ideas.

About Miracor Medical Systems GmBH:

Miracor Medical Systems GmbH is an Austrian medical device company that has developed  the PiCSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function. The system consists of a driving console and associated catheters. The company is currently conducting post-market clinical trials in Europe  to generate further clinical data and enlarge its user base utilizing the PiCSOAMI Therapy in heart attack patients undergoing coronary revascularization with stenting.

 

Contacts:

Peppermint VenturePartners GmbH

Dr. Joachim Rautter, Managing Partner

Kurfürstendamm 21

10719 Berlin

Phone: +49 30 590064 411

jr@peppermint-vp.com

www.peppermint-vp.com

 

Miracor Medical Systems GmbH

Olivier Delporte, CEO

odelporte@miracormedical.com

 

Press release PVP Miracor